Filing identity and reporting period
Important source mismatch: The request identifies GT Biopharma, Inc. and 2013 Q1, but the supplied filing is for OXIS International, Inc. It reports the quarter and nine months ended September 30, 2014, compared with the same periods in 2013. This summary reflects the supplied filing, not the requested company or period.
Business context
OXIS described its business as developing and selling or licensing products related to oxidative stress and inflammation, with a focus on ergothioneine-based products. Management also described a cannabinoid drug-development initiative through its subsidiary, OXIS Biotech. The company reported one operating segment.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2014 | Nine months ended Sep. 30, 2014 |
|---|---|---|
| Revenue | $3,000 | $28,000 |
| Gross profit (loss) | $(2,000) | $6,000 |
| Operating expenses | $547,000 | $760,000 |
| Operating loss | $(549,000) | $(754,000) |
| Interest expense | $3,263,000 | $3,628,000 |
| Net loss | $(4,220,000) | $(4,853,000) |
- Nine-month gross margin was approximately 21%; third-quarter gross margin was negative. The filing reported no research and development expense in either period.
- Cash and cash equivalents were $664,000 at September 30, 2014, versus $43,000 at December 31, 2013. Nine-month operating cash use was $711,000; financing provided $1,329,000. The cash-flow statement labels the $621,000 net change a decrease, although its beginning and ending cash balances show an increase of $621,000.
- Current liabilities were $11.308 million, including $4.942 million of non-cash warrant liability; total liabilities were $11.614 million. Management stated a cash-basis working capital deficit of $5.676 million. Accumulated deficit was $94.320 million.
- Stockholders’ deficit was $10.904 million. Common shares outstanding were reported as 591,714,484 at September 30, 2014.
Changes versus prior comparable periods
- Nine-month revenue fell to $28,000 from $327,000; third-quarter revenue fell to $3,000 from $183,000. Management said the company was evaluating product marketability and that these revenue comparisons might not indicate future operations.
- Nine-month net loss widened to $4.853 million from $147,000. Interest expense rose to $3.628 million from $1.002 million, primarily due to non-cash debt-discount amortization and interest on new notes.
- The nine-month change in warrant and derivative liabilities was a $468,000 expense, compared with a $1.365 million gain in 2013. Third-quarter SG&A rose to $547,000 from $200,000, primarily due to consulting and professional fees.
Outlook, risks, contingencies, and unusual items
- Going concern: Management said the current cash-use rate raised substantial doubt about the company’s ability to continue as a going concern without significant cash flows. It planned to seek additional equity or debt financing and increase revenues through new nutraceutical products, but gave no assurance of obtaining financing or generating sufficient revenue.
- Financing and dilution: The company issued convertible debentures and warrants during 2014, including a July financing with $1.25 million face amount and warrants for up to 178.6 million shares; it also issued its CEO a $175,000 debenture in settlement of accrued salary and fees. The filing reported 806.4 million warrants outstanding at September 30. It excluded 835.6 million potentially dilutive shares from diluted loss per share because they were anti-dilutive.
- Subsequent events: In October 2014, the company reported three additional convertible debentures with total face amount of $1.25 million and warrants. Also on October 24, it reached a resolution of a licensing-rights dispute under which it would receive a cash payment and a perpetual royalty; the payment amount and royalty terms are not clear in the supplied filing text.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective as of September 30, 2014, citing material weaknesses, including inadequate segregation of duties and risk of executive override.
- Other commitments: The filing describes potential milestone payments and royalties under an ARDS joint venture. It reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is OXIS International’s 2014 third-quarter Form 10-Q, not GT Biopharma’s 2013 first-quarter filing.
- Review the going-concern disclosure, cash runway, financing availability, and terms and priority of outstanding debt.
- Assess potential dilution from convertible instruments, warrants, and the company’s limited authorized common-share capacity.
- Verify the October licensing-dispute settlement’s cash consideration and royalty terms, and the terms and funding proceeds of the October debentures.
- Review remediation of the disclosed material weaknesses and reconcile the cash-flow statement’s net-change label with reported beginning and ending cash.